Viral vector manufacturing represents the sophisticated process of producing modified viruses that serve as delivery vehicles for therapeutic genetic material. These engineered vectors have revolutionised gene therapy applications, from treating rare genetic disorders to developing next-generation vaccines, including the COVID-19
Terminal sterilisation is a cornerstone of sterile drug product manufacturing. Recognised by regulatory authorities as the preferred sterilisation method, it offers unparalleled sterility assurance when applied appropriately. The global terminal sterilisation services market is projected to grow from USD 13.09
The contract pharmaceutical packaging market is growing, and quickly. In this article, Dexter Tjoa, CEO of Tjoapack will explore the challenges facing pharmaceutical companies as a result of recent industry trends and will explain how expert support from CPO partners
Lyophilisation, commonly referred to as freeze-drying, is a critical technique in pharmaceutical manufacturing that enables the long-term stabilisation of sensitive drug products. As the pharmaceutical and biotech industries continue to develop increasingly complex biologics, the demand for robust preservation techniques
Cell line development represents one of the most critical foundational processes in modern biopharmaceutical manufacturing, serving as the backbone for producing life-saving therapeutics from monoclonal antibodies to gene therapies. This intricate process transforms living cells into highly productive biological factories,
Sponsored by Prasfarma In the highly regulated world of pharmaceuticals, analytical development plays a pivotal role in Investigational Medicinal Product Dossier (IMPD) projects. These projects are critical for obtaining clinical trial authorization and ensuring the safety, efficacy, and quality of
Pentixapharm, a clinical-stage biopharmaceutical company, has announced a manufacturing agreement with Eckert & Ziegler Radiopharma GmbH (EZR), a subsidiary of Eckert & Ziegler SE. Under the deal, EZR will produce patient-specific doses of Y90-PentixaTher, Pentixapharm’s CXCR4-targeting radiotherapeutic, for use in clinical trials.
CN Bio has announced a strategic partnership with Pharmaron, aimed at validating and deploying its PhysioMimix Organ-on-a-Chip (OOC) platform across Pharmaron’s global R&D sites. The agreement also includes plans to co-develop new applications to support unmet needs in drug discovery and
Integer Holdings Corporation has announced a planned leadership transition, with President and Chief Executive Officer Joseph Dziedzic set to retire effective 24 October 2025. Payman Khales, currently Chief Operating Officer, will succeed Dziedzic as CEO and join the company’s Board of
Thermo Fisher Scientific Inc., a major global player in the life sciences sector, has announced plans to invest $2 billion in its U.S. operations over the next four years. The investment is aimed at bolstering American innovation, enhancing manufacturing capacity,
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
